You are here:

Grzegorz (Greg) Bulaj

Associate Professor of Medicinal Chemistry and
Research Associate Professor of Biology and
Adjunct Assistant Professor of Anesthesiology

Greg Bulaj

M.Sc. University of Wroclaw, Poland

Ph.D. University of Wroclaw, Poland

Research

References

bulaj@pharm.utah.edu

Greg Bulaj's Lab Page

Greg Bulaj's PubMed Literature Search

Biological Chemistry Program

Molecular-Behavioral Combination Therapies; Epilepsy; Cancer; Depression; Digital Health; Mobile Medical Apps

Research

The long-term goal of our research is to develop a drug-device combination therapy which simultaneously targets a disease at both molecular and behavioral levels. The molecular-behavioral combination therapies consist of pharmaceutical drugs and disease self-management content which is delivered via digital/mobile medical devices. This strategy aims to improve both therapy outcomes and medication adherence for chronically-ill patients. Our current research includes creating clinical and self-care content for medical devices to be combined with cancer chemotherapy, or with antiepileptic drugs. Examples of our collaborative projects include: (1) an exercise-empowerment mobile game therapy for pediatric oncology patients, and (2) mobile software for epilepsy patients.

References

  1. Schriewer K and Bulaj G (2016) Music Streaming Services as Adjunct Therapies for Depression, Anxiety and Bipolar Symptoms: Convergence of Digital Technologies, Mobile Apps, Emotions, and Global Mental Health. Front Publ Health. 4: 217. journal.frontiersin.org/article/10.3389/fpubh.2016.00217/full

  2. Bulaj G, Ahern MM, Kuhn A, Judkins ZS, Bowen RC, Chen Y. (2016) Incorporating Natural Products, Pharmaceutical Drugs, Self-care and Digital/Mobile Health Technologies into Molecular-Behavioral Combination Therapies for Chronic Diseases. Curr Clin Pharmacol 11: 1-18 http://www.eurekaselect.com/142876
  3. Lee HK, Zhang L, Smith MD, Walewska A, Vellore NA, Baron R, McIntosh JM, White HS, Olivera BM, Bulaj G (2015) A marine analgesic peptide, Contulakin-G and neurotensin are distinct agonists for neurotensin receptors: uncovering structural determinants of desensitization properties. Front Pharmacol 6: 11 http://journal.frontiersin.org/article/10.3389/fphar.2015.00011/full
  4. Govender M, Bowen RC, German ML, Bulaj G, Bruggers CS (2015) Clinical and Neurobiological Perspectives of Empowering Pediatric Cancer Patients Using Videogames. Games Health J. 4: 1-13 http://online.liebertpub.com/doi/pdfplus/10.1089/g4h.2015.0014
  5. Bulaj G (2014) Combining non-pharmacological treatments with pharmacotherapies for neurological disorders: a unique interface of the brain, drug–device, and intellectual property. Front Neurol. 5: 126 
http://journal.frontiersin.org/Journal/10.3389/fneur.2014.00126/full
  6. Zhang L, Klein BD, Metcalf CS, Smith MD, McDougle DR, Lee HK, White HS, Bulaj G (2013) Incorporation of monodisperse oligoethyleneglycol amino acids into anticonvulsant analogues of galanin and neuropeptide y provides peripherally acting analgesics. Mol Pharm. 10: 574-85
  7. Bruggers CS, Altizer RA, Kessler RR, Caldwell CB, Coppersmith K, Warner L, Davies B, Paterson W, Wilcken J, D'Ambrosio TA, German ML,Hanson GR, Gershan LA, Korenberg JR, Bulaj G (2012) Patient-empowerment interactive technologies. Sci Transl Med. 4(152): 152ps16 http://stm.sciencemag.org/content/4/152/152ps16.full
  8. Robertson CR, Scholl EA, Pruess TH, Green BR, White HS, Bulaj G (2010) Engineering Galanin Analogues that Discriminate between GalR1 and GalR2 Receptor Subtypes and Exhibit Anticonvulsant Activity following Systemic Delivery. J Med Chem. 53: 1871-5

to page top

Last Updated: 8/11/17